Cellus Inc. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.

Q-901 is under clinical development by Qurient and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate ...

Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase ...

Exscientia's near-term prospects are closely tied to the progress of its clinical programs, particularly its CDK7 inhibitor and MALT1 inhibitor programs. The company is on track to release initial ...

Exscientia’s current clinical-stage pipeline consists of CDK7 inhibitor GTAEXS-617, which is co-owned with GT Apeiron, Evotec-partnered A2A receptor antagonist EXS-21546, and BMS-partnered PKC ...

(NASDAQ: RXRX), a clinical stage TechBio company, recently announced interim data from the Phase 1/2 ELUCIDATE trial of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The trial ...

Shanghai Institute of Organic Chemistry has described leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory ...

USA News Group News Commentary ? Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...